1. Home
  2. IBRX
  3. IBRX News

Latest ImmunityBio Inc. (IBRX) News on September 18, 2025

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
IBRX

Business Wire

10 days ago

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study
IBRX

Simply Wall St.

12 days ago

A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA
IBRX

Insider Monkey

3 months ago

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA

Exploring High Growth Tech Stocks In The US Market
IBRX

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks In The US Market

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
IBRX

Insider Monkey

3 months ago

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today

ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield
IBRX

TipRanks

3 months ago

ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
IBRX

Business Wire

3 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
IBRX

Business Wire

4 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
IBRX

Business Wire

4 months ago

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT
IBRX

Insider Monkey

4 months ago

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT

Exploring 3 High Growth Tech Stocks In The US Market
IBRX

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00
IBRX

Simply Wall St.

4 months ago

Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
IBRX

Business Wire

4 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
IBRX

Business Wire

4 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
IBRX

Business Wire

5 months ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Astera Labs And Two More Top Growth Companies With Strong Insider Ownership
IBRX

Simply Wall St.

5 months ago

Astera Labs And Two More Top Growth Companies With Strong Insider Ownership

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
IBRX

Business Wire

5 months ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
IBRX

Business Wire

5 months ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple
IBRX

Insider Monkey

5 months ago

ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
IBRX

Business Wire

5 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
IBRX

Business Wire

5 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Exploring US High Growth Tech Stocks In April 2025
IBRX

Simply Wall St.

5 months ago

Exploring US High Growth Tech Stocks In April 2025

ImmunityBio to Host Investor Day
IBRX

Business Wire

6 months ago

ImmunityBio to Host Investor Day

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
IBRX

Business Wire

6 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Top Growth Companies With Insider Stakes For March 2025
IBRX

Simply Wall St.

6 months ago

Top Growth Companies With Insider Stakes For March 2025

US High Growth Tech Stocks to Watch in March 2025
IBRX

Simply Wall St.

6 months ago

US High Growth Tech Stocks to Watch in March 2025

ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
IBRX

Simply Wall St.

6 months ago

ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
IBRX

Business Wire

7 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
IBRX

Business Wire

7 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz
IBRX

TipRanks

7 months ago

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
IBRX

Business Wire

7 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
IBRX

Business Wire

7 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
IBRX

Business Wire

8 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Exploring High Growth Tech Stocks in the United States
IBRX

Simply Wall St.

8 months ago

Exploring High Growth Tech Stocks in the United States

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
IBRX

Business Wire

8 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
IBRX

Business Wire

8 months ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
IBRX

Business Wire

8 months ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
IBRX

Business Wire

8 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

High Growth Tech Stocks to Watch in December 2024
IBRX

Simply Wall St.

9 months ago

High Growth Tech Stocks to Watch in December 2024

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
IBRX

GlobeNewswire

9 months ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
IBRX

Business Wire

9 months ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
IBRX

Business Wire

9 months ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds
IBRX

Insider Monkey

10 months ago

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
IBRX

PR Newswire

10 months ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

High Growth Tech Stocks To Watch In November 2024
IBRX

Simply Wall St.

10 months ago

High Growth Tech Stocks To Watch In November 2024

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
IBRX

Business Wire

10 months ago

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

ImmunityBio Reports Third-Quarter 2024 Financial Results
IBRX

Business Wire

10 months ago

ImmunityBio Reports Third-Quarter 2024 Financial Results

IBRX

GuruFocus.com

a year ago

ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
IBRX

Business Wire

a year ago

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio to Participate in the Jefferies London Healthcare Conference
IBRX

Business Wire

a year ago

ImmunityBio to Participate in the Jefferies London Healthcare Conference

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
IBRX

Business Wire

a year ago

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
IBRX

Business Wire

a year ago

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
IBRX

Business Wire

a year ago

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop
IBRX

Simply Wall St.

a year ago

Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
IBRX

Business Wire

a year ago

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
IBRX

Business Wire

a year ago

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
IBRX

Business Wire

a year ago

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
IBRX

Simply Wall St.

a year ago

ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
IBRX

Business Wire

a year ago

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
IBRX

Business Wire

a year ago

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
IBRX

Business Wire

a year ago

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
IBRX

Business Wire

a year ago

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

ImmunityBio's bladder cancer therapy wins FDA approval
IBRX

Yahoo Finance Video

a year ago

ImmunityBio's bladder cancer therapy wins FDA approval

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
IBRX

Business Wire

a year ago

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
IBRX

Business Wire

2 years ago

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
IBRX

Business Wire

2 years ago

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
IBRX

Business Wire

2 years ago

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?
IBRX

Simply Wall St.

2 years ago

ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
IBRX

Business Wire

2 years ago

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

‘Kubrick’ Review: The Perfectionist and His Craft
IBRX

The Wall Street Journal

2 years ago

‘Kubrick’ Review: The Perfectionist and His Craft

Trump Tower Lender Calls Fear of Bank Property Turmoil Overblown
IBRX

Bloomberg

2 years ago

Trump Tower Lender Calls Fear of Bank Property Turmoil Overblown

New Strong Buy Stocks for February 2nd
IBRX

Zacks

2 years ago

New Strong Buy Stocks for February 2nd

IBRX

Associated Press Finance

2 years ago

Cavco: Fiscal Q3 Earnings Snapshot

AMN Healthcare to Hold Fourth Quarter and Full Year 2023 Earnings Conference Call on Thursday, February 15, 2024
IBRX

GlobeNewswire

2 years ago

AMN Healthcare to Hold Fourth Quarter and Full Year 2023 Earnings Conference Call on Thursday, February 15, 2024

Cavco Industries Reports Fiscal 2024 Third Quarter Results and Announces New $100 Million Stock Repurchase Program
IBRX

GlobeNewswire

2 years ago

Cavco Industries Reports Fiscal 2024 Third Quarter Results and Announces New $100 Million Stock Repurchase Program

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
IBRX

Investor's Business Daily

2 years ago

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Constellium to Report Fourth Quarter and Full Year 2023 Results on February 21, 2024
IBRX

GlobeNewswire

2 years ago

Constellium to Report Fourth Quarter and Full Year 2023 Results on February 21, 2024

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story
IBRX

Motley Fool

2 years ago

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

IBRX

GlobeNewswire

2 years ago

Simplicity Group Unveils WeDYOR: Transforming Due Diligence for Crypto Investments

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis
IBRX

GlobeNewswire

2 years ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

IBRX

Business Wire

2 years ago

Form 8.3 - DX (Group) plc

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research
IBRX

GlobeNewswire

2 years ago

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030
IBRX

GlobeNewswire

2 years ago

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit
IBRX

Barrons.com

2 years ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree
IBRX

Zacks

2 years ago

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree

Will Aercap (AER) Skyrocket in 2024?
IBRX

Insider Monkey

2 years ago

Will Aercap (AER) Skyrocket in 2024?

Baillie Gifford Bolsters Stake in ODDITY Tech Ltd
IBRX

GuruFocus.com

2 years ago

Baillie Gifford Bolsters Stake in ODDITY Tech Ltd

Spire Declares Dividend
IBRX

PR Newswire

2 years ago

Spire Declares Dividend

3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024
IBRX

InvestorPlace

2 years ago

3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024

PGT Innovations Named on Forbes’ America's Most Successful Small-Cap Companies List
IBRX

Business Wire

2 years ago

PGT Innovations Named on Forbes’ America's Most Successful Small-Cap Companies List

Travel companies are using AI to better customize trip itineraries
IBRX

Fortune

2 years ago

Travel companies are using AI to better customize trip itineraries

Upskilling the future of India’s construction industry
IBRX

GlobeNewswire

2 years ago

Upskilling the future of India’s construction industry

Intuitive Surgical Full Year 2023 Earnings: EPS Beats Expectations
IBRX

Simply Wall St.

2 years ago

Intuitive Surgical Full Year 2023 Earnings: EPS Beats Expectations

Zacks Investment Ideas feature highlights: Intuitive Surgical
IBRX

Zacks

2 years ago

Zacks Investment Ideas feature highlights: Intuitive Surgical

MPLX LP Announces Quarterly Distribution
IBRX

PR Newswire

2 years ago

MPLX LP Announces Quarterly Distribution

United Community Banks (UCBI) Reports Q4 Earnings: What Key Metrics Have to Say
IBRX

Zacks

2 years ago

United Community Banks (UCBI) Reports Q4 Earnings: What Key Metrics Have to Say

IBRX

Business Wire

2 years ago

Fortive Declares Regular Quarterly Dividend on its Common Stock

IBRX

Business Wire

2 years ago

Fortive Announces Replenishment of Share Repurchase Authorization

CNH Brand Unveils Innovative Suite of Solutions for Digital Agriculture
IBRX

ACCESSWIRE

2 years ago

CNH Brand Unveils Innovative Suite of Solutions for Digital Agriculture

IBRX

Business Wire

2 years ago

Douglas Emmett Announces 2023 Tax Treatment of Dividends

Share on Social Networks: